Here are four things to know:
1. The organizations are concerned, if passed, the legislation will undermine drug safety protection.
2. The proposed legislation is intended to accelerate the development of less expensive generic drugs.
3. Due to the sped-up process, the patient advocates are worried the legislation will eliminate established procedures for generic manufacturers to adopt safety protocols.
4. Supporters and members of the Patients’ Alliance for Drug Safety Protections wrote a joint letter to the Senate Judiciary Committee, noting the legislation will hurt the FDA’s authority to regulate high-risk drugs.
Read about the letter’s specifics here.
More articles on quality & infection control:
Medicare spending on nonfatal falls reaches $31B — 5 notes on the falling epidemic
Where to focus your compliance efforts: Part one
10 top ASC citations by the Ohio Department of Health
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.